Abstract
Studies focused on patient responsiveness to antiplatelet therapies, particularly aspirin and clopidogrel, have increased in recent years. However, the relations of in vivo platelet function and adverse clinical events to results of ex vivo platelet function tests remain largely unknown. This article describes current methods of measuring platelet function in various clinical and research situations and their advantages and disadvantages, reviews evidence for antiplatelet response variability and resistance, discusses the potential pitfalls of monitoring platelet function, and demonstrates emerging data supporting the positive clinical and treatment implications of platelet function testing.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Acute Coronary Syndrome / blood
-
Acute Coronary Syndrome / drug therapy
-
Aspirin / adverse effects
-
Aspirin / therapeutic use
-
Clopidogrel
-
Coronary Artery Disease / blood
-
Coronary Artery Disease / drug therapy
-
Coronary Disease / blood*
-
Coronary Disease / drug therapy
-
Drug Resistance
-
Humans
-
Monitoring, Physiologic*
-
Myocardial Infarction / blood
-
Myocardial Infarction / drug therapy
-
Platelet Aggregation Inhibitors / adverse effects
-
Platelet Aggregation Inhibitors / therapeutic use
-
Platelet Function Tests*
-
Platelet Glycoprotein GPIIb-IIIa Complex / antagonists & inhibitors
-
Risk Factors
-
Ticlopidine / adverse effects
-
Ticlopidine / analogs & derivatives
-
Ticlopidine / therapeutic use
-
Treatment Outcome
Substances
-
Platelet Aggregation Inhibitors
-
Platelet Glycoprotein GPIIb-IIIa Complex
-
Clopidogrel
-
Ticlopidine
-
Aspirin